$-1.19 EPS Expected for Theravance Biopharma, Inc. (TBPH); Hilltop Holdings Inc. (HTH) Had 2 Analysts Last Week

April 10, 2018 - By Vivian Park

Theravance Biopharma, Inc. (NASDAQ:TBPH) Logo

Analysts expect Theravance Biopharma, Inc. (NASDAQ:TBPH) to report $-1.19 EPS on May, 8.They anticipate $0.08 EPS change or 6.30% from last quarter’s $-1.27 EPS. After having $-1.64 EPS previously, Theravance Biopharma, Inc.’s analysts see -27.44% EPS growth. The stock increased 1.64% or $0.365 during the last trading session, reaching $22.595. About 86,905 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 26.76% since April 10, 2017 and is downtrending. It has underperformed by 38.31% the S&P500.

Among 7 analysts covering Hilltop Holdings (NYSE:HTH), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Hilltop Holdings had 24 analyst reports since August 4, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 4 by Piper Jaffray. The firm has “Mkt Perform” rating by FBR Capital given on Friday, October 28. The rating was maintained by Piper Jaffray with “Hold” on Sunday, January 28. The firm has “Hold” rating given on Thursday, February 15 by Stephens. Piper Jaffray downgraded the stock to “Neutral” rating in Wednesday, May 10 report. As per Wednesday, November 23, the company rating was downgraded by Compass Point. The firm earned “Hold” rating on Thursday, December 21 by Keefe Bruyette & Woods. The stock has “Buy” rating by Stephens on Friday, July 28. The company was downgraded on Thursday, December 17 by Raymond James. SunTrust maintained the shares of HTH in report on Sunday, October 29 with “Buy” rating. See Hilltop Holdings Inc. (NYSE:HTH) latest ratings:

15/02/2018 Broker: Stephens Rating: Hold New Target: $29.0 Maintain
29/01/2018 Broker: Stephens Old Rating: Overweight New Rating: Equal-Weight Downgrade
28/01/2018 Broker: Piper Jaffray Rating: Hold New Target: $30.0 Maintain
08/01/2018 Broker: SunTrust Rating: Buy New Target: $29.0 Maintain
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $30.0 Maintain
29/10/2017 Broker: SunTrust Rating: Buy New Target: $28.0 Maintain

Investors sentiment decreased to 1.31 in Q4 2017. Its down 0.01, from 1.32 in 2017Q3. It dived, as 7 investors sold Theravance Biopharma, Inc. shares while 22 reduced holdings. 12 funds opened positions while 26 raised stakes. 35.06 million shares or 1.11% less from 35.46 million shares in 2017Q3 were reported. Geode Cap Management Ltd Company holds 373,476 shares or 0% of its portfolio. Blackrock invested in 3.74M shares. Bnp Paribas Asset Mngmt Holdg Sa holds 0.04% or 176,192 shares in its portfolio. 113,862 were accumulated by Old West Invest Mgmt Llc. Deutsche Bank & Trust Ag accumulated 108,750 shares. State Board Of Administration Of Florida Retirement Sys has invested 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). 31,000 are held by State Of Wisconsin Inv Board. Schwab Charles Invest Mngmt holds 199,677 shares. Sei Investments Com reported 8 shares. Fmr Limited Co holds 0.03% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 7.95M shares. Alliancebernstein L P accumulated 61,235 shares. Moreover, Morgan Stanley has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH). 24,500 were accumulated by Dekabank Deutsche Girozentrale. Senzar Asset Mgmt Ltd holds 171,800 shares or 1.22% of its portfolio. Rhumbline Advisers holds 0% or 38,654 shares.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.24 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

Among 8 analysts covering Theravance Biopharma (NASDAQ:TBPH), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Theravance Biopharma had 22 analyst reports since August 12, 2015 according to SRatingsIntel. Needham maintained the shares of TBPH in report on Wednesday, November 8 with “Buy” rating. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) earned “Buy” rating by Needham on Friday, September 15. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, November 7. As per Wednesday, December 21, the company rating was initiated by Needham. The firm has “Buy” rating by Cantor Fitzgerald given on Wednesday, July 19. The rating was maintained by Robert W. Baird with “Sell” on Monday, October 30. Cantor Fitzgerald maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) rating on Wednesday, August 16. Cantor Fitzgerald has “Buy” rating and $55.0 target. The stock has “Neutral” rating by Robert W. Baird on Wednesday, August 12. The company was initiated on Monday, August 29 by Evercore. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) has “Outperform” rating given on Thursday, February 8 by Leerink Swann.

Hilltop Holdings Inc. provides business and consumer banking services in Texas, California, Florida, Ohio, Washington, Arizona, Maryland, North Carolina, and other states. The company has market cap of $2.26 billion. The Company’s Banking segment offers savings, checking, interest-bearing checking, and money market accounts; certificates of deposit; lines and letters of credit, home improvement and equity loans, and loans for purchasing and carrying securities, equipment loans and leases, agricultural and commercial real estate loans, and other loans; and commercial, industrial, and single family residential mortgage loans. It has a 17.3 P/E ratio. This segment also provides term finance on commercial real estate properties; construction finance; treasury management; and check cards, safe deposit boxes, Internet banking, bill pay, overdraft, and automated teller machine services.

The stock increased 2.08% or $0.48 during the last trading session, reaching $23.53. About 103,290 shares traded. Hilltop Holdings Inc. (NYSE:HTH) has declined 11.90% since April 10, 2017 and is downtrending. It has underperformed by 23.45% the S&P500.

Investors sentiment decreased to 1.03 in Q4 2017. Its down 0.10, from 1.13 in 2017Q3. It is negative, as 19 investors sold Hilltop Holdings Inc. shares while 41 reduced holdings. 15 funds opened positions while 47 raised stakes. 53.11 million shares or 1.30% more from 52.43 million shares in 2017Q3 were reported. Ftb Advisors holds 0% or 81 shares. Victory Cap owns 9,789 shares. Credit Suisse Ag owns 44,919 shares for 0% of their portfolio. Great West Life Assurance Can, a Manitoba – Canada-based fund reported 10,163 shares. Swiss National Bank & Trust reported 0% of its portfolio in Hilltop Holdings Inc. (NYSE:HTH). Wells Fargo And Mn holds 0% of its portfolio in Hilltop Holdings Inc. (NYSE:HTH) for 335,914 shares. Menta Capital Lc owns 58,968 shares. Dimensional Fund Advsrs Lp reported 0.06% of its portfolio in Hilltop Holdings Inc. (NYSE:HTH). Nwq Inv Management Lc accumulated 803,453 shares or 0.26% of the stock. Guggenheim Capital Limited invested in 0% or 42,918 shares. Banc Funds Com Limited Com has 227,532 shares. Royal Bank Of Canada reported 0% of its portfolio in Hilltop Holdings Inc. (NYSE:HTH). Federated Investors Pa holds 0.03% in Hilltop Holdings Inc. (NYSE:HTH) or 479,638 shares. First Manhattan Co reported 0% of its portfolio in Hilltop Holdings Inc. (NYSE:HTH). Parallax Volatility Advisers L P accumulated 11,172 shares.

Hilltop Holdings Inc. (NYSE:HTH) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>